Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.97 USD
Change Today +0.02 / 0.29%
Volume 24.1K
CPIX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

cumberland pharmaceuticals (CPIX) Key Developments

Cumberland Pharmaceuticals, Inc. Announces the Results from the Hepatoren Phase II Study

Cumberland Pharmaceuticals, Inc. announced the achievement of several clinical and regulatory milestones. These developments include top-line results from the company’s hepatoren phase ii study, submission of a supplemental new drug application (snda) with pediatric data for caldolor, and initiation of patient enrollment in the boxaban phase II clinical trial. The company completed enrollment in the first of two patient cohorts of its phase ii study of hepatoren in patients with hepatorenal syndrome (hrs). the phase ii double-blind, multi-center, randomized, controlled study evaluated the pharmacokinetics, safety and tolerability of ifetroban administered as daily intravenous doses in hrs patients. patients were stratified based upon disease type, either type i or type ii hrs diagnosis - with four dosing cohorts per disease type. enrollment for type ii hrs patients was completed at the end of 2014. Top line results from the type ii patient cohort indicate that ifetroban was overall well tolerated with no safety concerns noted. furthermore, the patients receiving the higher dose levels of ifetroban were more likely to experience increases in urine output, a signal of improvement in kidney function, compared to patients who received placebo. based on these results, cumberland will proceed with clinical development of this product candidate. The company recently completed a series of phase iv studies for caldolor in more than 1,000 patients in over 30 medical centers across the u.s. these studies included evaluation of the product in both children and adults. following the completion of these phase iv studies, the company submitted a snda to the fda for the product. this submission requested changes to the package insert to include pediatric data from the company's post-marketing pediatric development program. in addition, the results from two caldolor phase iv adult studies were recently published and are currently available as manuscripts in the journal clinical therapeutics. The company recently announced an expansion of its pipeline with a new phase ii development program. the company has begun the clinical development of boxaban for the treatment of aspirin-exacerbated respiratory disease (aerd). aerd is a respiratory disease involving chronic asthma and nasal polyposis that is worsened by aspirin. it is characterized by sharp increases in inflammatory mediators and platelet activity within the respiratory system. ifetroban, an active thromboxane receptor antagonist, may interfere with these pathways to modify the disease and provide symptomatic relief.

Cumberland Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Cumberland Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net revenue of $9,329,412 against $8,159,667 for the prior year period. Operating income was $946,138 against loss of $2,472,077 for the prior year period. Income before income taxes was $976,977 compared to loss before income taxes of $2,444,196 for the same period a year ago. Net income attributable to common shareholders was $668,913 or $0.04 per diluted share compared to net loss attributable to common shareholders of $1,500,363 or $0.08 per diluted share, for the prior year period. For the full year, the company reported net revenue of $36,901,871 against $32,027,462 for the prior year period. Operating income was $3,558,836 against loss of $3,801,338 for the prior year period. Income before income taxes was $3,743,209 compared to loss before income taxes of $3,674,469 for the same period a year ago. Net income attributable to common shareholders was $2,423,723 or $0.14 per diluted share compared to net loss attributable to common shareholders of $2,104,614 or $0.11 per diluted share, for the prior year period. Net cash provided by operating activities was $6,693,431 compared to $746,126 for the same period a year ago. Additions to property and equipment were $163,258 compared to $97,412 for the same period a year ago. Additions to intangible assets were $3,101,565 compared to $7,462,080 for the same period a year ago.

Cumberland Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 03, 2015

Cumberland Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Mar 03, 2015

Cumberland Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 03, 2015

Cumberland Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 03, 2015

Cumberland Pharmaceuticals Announces Pipeline Expansion with Boxaban™ (Ifetroban) Oral Capsule

Cumberland Pharmaceuticals Inc. announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Cumberland has completed manufacturing and received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) submission and Phase II study associated with the product. Aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad, is a respiratory disease involving chronic asthma and nasal polyposis that is worsened by aspirin or nonsteroidal anti-inflammatory drugs. Approximately one in 20 asthmatic adults (nearly 1 million patients in the United States) suffer from AERD and the disease awareness is growing within the medical community. AERD is characterized by sharp increases in inflammatory mediators and platelet activity within the respiratory system. Ifetroban, an active thromboxane receptor antagonist, may interfere with these pathways to modify the disease and provide symptom relief. Current treatment of AERD remains a challenge, as novel and effective treatment modalities are lacking for this unmet medical need.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPIX:US $6.97 USD +0.02

CPIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $55.24 USD -0.68
Durect Corp $2.11 USD -0.46
Ironwood Pharmaceuticals Inc $15.11 USD -0.37
Pacira Pharmaceuticals Inc/DE $85.07 USD +0.80
Sucampo Pharmaceuticals Inc $21.09 USD -0.31
View Industry Companies
 

Industry Analysis

CPIX

Industry Average

Valuation CPIX Industry Range
Price/Earnings 51.5x
Price/Sales 3.3x
Price/Book 1.5x
Price/Cash Flow 29.4x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUMBERLAND PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.